Clinical Trial Update: Sorafenib, Busulfan and Fludarabine in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia Undergoing Donor Stem Cell Transplant [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial evaluating a combination of sorafenib, busulfan, and fludarabine as conditioning therapy for patients with recurrent or refractory ac…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• Busulfex (busulfan)
• Fludara (fludarabine)
• Nexavar (Sorafenib)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING